These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 20828543)
1. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Xiao D; Cassin JJ; Healy B; Burdett TC; Chen JF; Fredholm BB; Schwarzschild MA Brain Res; 2011 Jan; 1367():310-8. PubMed ID: 20828543 [TBL] [Abstract][Full Text] [Related]
2. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats. Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528 [TBL] [Abstract][Full Text] [Related]
3. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats. Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908 [TBL] [Abstract][Full Text] [Related]
4. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Ravenscroft P; Chalon S; Brotchie JM; Crossman AR Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317 [TBL] [Abstract][Full Text] [Related]
5. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199 [TBL] [Abstract][Full Text] [Related]
6. l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons. Klietz M; Keber U; Carlsson T; Chiu WH; Höglinger GU; Weihe E; Schäfer MK; Depboylu C Neuroscience; 2016 Sep; 331():120-33. PubMed ID: 27320210 [TBL] [Abstract][Full Text] [Related]
7. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021 [TBL] [Abstract][Full Text] [Related]
8. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910 [TBL] [Abstract][Full Text] [Related]
9. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Pavón N; Martín AB; Mendialdua A; Moratalla R Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809 [TBL] [Abstract][Full Text] [Related]
10. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
12. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum. Wang Y; Wang HS; Wang T; Huang C; Liu J J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553 [TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747 [TBL] [Abstract][Full Text] [Related]
14. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725 [TBL] [Abstract][Full Text] [Related]
15. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702 [TBL] [Abstract][Full Text] [Related]
16. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Zhang K; Chammas C; Soghomonian JJ Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284 [TBL] [Abstract][Full Text] [Related]
17. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. Lundblad M; Vaudano E; Cenci MA J Neurochem; 2003 Mar; 84(6):1398-410. PubMed ID: 12614340 [TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Kobylecki C; Crossman AR; Ravenscroft P Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800 [TBL] [Abstract][Full Text] [Related]
19. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. Xiao D; Bastia E; Xu YH; Benn CL; Cha JH; Peterson TS; Chen JF; Schwarzschild MA J Neurosci; 2006 Dec; 26(52):13548-55. PubMed ID: 17192438 [TBL] [Abstract][Full Text] [Related]
20. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease. Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]